Equillium Capital Raise of $20M
Equillium triggered a $20 million milestone closing of a previously announced private placement following the dosing of the first patient in its Phase 1 clinical trial of EQ504. The company is issuing approximately 14.9 million shares and 20.1 million pre-funded warrants to institutional and accredited investors. The proceeds are expected to extend the company's cash runway into 2029.
- Value
- $20M